Outcomes after definitive treatment for head and neck angiosarcoma

Area of Science:

• Oncology
• Head and Neck Cancer Research
• Rare Malignancies

Background:

• Head and neck angiosarcoma (HN-AS) is a rare (<1%) and aggressive malignancy.
• HN-AS is associated with high recurrence rates and poor 5-year survival (10-54%).
• Limited Australian data exists for this specific cancer type.

Purpose of the Study:

• To review treatment patterns and clinical outcomes of HN-AS patients in Australia.
• To analyze survival data and identify prognostic factors for HN-AS.
• To provide the first Australian report on HN-AS treatment and outcomes.

Main Methods:

• Retrospective chart review of 26 HN-AS patients from two Australian high-volume head and neck cancer units.
• Analysis of patient demographics, tumor characteristics, treatment modalities, and survival outcomes (Overall Survival, Disease-Free Survival).
• Statistical comparison of outcomes based on treatment approaches (surgery + adjuvant vs. chemoradiotherapy).

Main Results:

• The cohort comprised predominantly male patients (81%) with a mean age of 77. Scalp was the most common primary site (62%).
• Five-year Overall Survival (OS) and Disease-Free Survival (DFS) were 41% and 15%, respectively.
• Patients treated with upfront surgery and adjuvant therapy demonstrated significantly better OS and DFS compared to those receiving upfront chemoradiotherapy (P=0.011 for OS, P=0.001 for DFS). Recurrence was observed in 57.7% of patients, with lung metastasis being common (80%).

Conclusions:

• This study represents the first Australian report on HN-AS treatment and outcomes.
• HN-AS is confirmed as a slowly progressive disease with poor survival rates.
• Upfront surgery followed by adjuvant therapy appears to yield better outcomes than chemoradiotherapy alone for HN-AS. Neoadjuvant chemotherapy's role requires further investigation.